Pfizer Inc. (NYSE:PFE) Shares Sold by GM Advisory Group LLC

GM Advisory Group LLC decreased its stake in shares of Pfizer Inc. (NYSE:PFE) by 14.0% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 30,732 shares of the biopharmaceutical company’s stock after selling 5,000 shares during the period. GM Advisory Group LLC’s holdings in Pfizer were worth $860,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Wealth Advisors of Tampa Bay LLC increased its stake in shares of Pfizer by 2.7% during the second quarter. Wealth Advisors of Tampa Bay LLC now owns 144,439 shares of the biopharmaceutical company’s stock valued at $4,041,000 after acquiring an additional 3,800 shares during the period. Trust Investment Advisors bought a new position in Pfizer during the 2nd quarter valued at $1,259,000. Ieq Capital LLC increased its position in shares of Pfizer by 15.6% during the 2nd quarter. Ieq Capital LLC now owns 224,636 shares of the biopharmaceutical company’s stock valued at $6,285,000 after purchasing an additional 30,388 shares during the period. Brighton Jones LLC raised its stake in shares of Pfizer by 800.9% in the 2nd quarter. Brighton Jones LLC now owns 1,101,586 shares of the biopharmaceutical company’s stock worth $30,822,000 after buying an additional 979,310 shares in the last quarter. Finally, Intech Investment Management LLC boosted its stake in Pfizer by 30.3% during the second quarter. Intech Investment Management LLC now owns 725,663 shares of the biopharmaceutical company’s stock valued at $20,304,000 after buying an additional 168,724 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors.

Pfizer Price Performance

PFE opened at $29.67 on Friday. The company has a current ratio of 0.86, a quick ratio of 0.60 and a debt-to-equity ratio of 0.65. Pfizer Inc. has a 1 year low of $25.20 and a 1 year high of $34.11. The stock has a fifty day moving average price of $29.35 and a 200 day moving average price of $28.20. The stock has a market cap of $168.13 billion, a price-to-earnings ratio of -494.42, a PEG ratio of 1.02 and a beta of 0.68.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, July 30th. The biopharmaceutical company reported $0.60 EPS for the quarter, topping analysts’ consensus estimates of $0.46 by $0.14. The firm had revenue of $13.28 billion for the quarter, compared to the consensus estimate of $12.96 billion. Pfizer had a positive return on equity of 8.42% and a negative net margin of 4.66%. The firm’s revenue was up 2.1% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.67 earnings per share. Analysts forecast that Pfizer Inc. will post 2.66 EPS for the current fiscal year.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, September 3rd. Investors of record on Friday, July 26th were paid a $0.42 dividend. This represents a $1.68 annualized dividend and a dividend yield of 5.66%. The ex-dividend date was Friday, July 26th. Pfizer’s payout ratio is presently -2,799.53%.

Analyst Ratings Changes

A number of equities research analysts have weighed in on PFE shares. Barclays upped their price target on shares of Pfizer from $30.00 to $32.00 and gave the company an “equal weight” rating in a report on Wednesday, July 31st. Daiwa Capital Markets upgraded shares of Pfizer from a “neutral” rating to an “outperform” rating and lifted their price target for the stock from $28.00 to $34.00 in a research report on Wednesday, August 7th. Wells Fargo & Company raised their price objective on Pfizer from $28.00 to $30.00 and gave the stock an “equal weight” rating in a research note on Wednesday, July 31st. Daiwa America raised Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research report on Wednesday, August 7th. Finally, UBS Group lifted their price target on Pfizer from $30.00 to $31.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 31st. Eight research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $34.54.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.